Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
November 2025 in “Journal of Investigative Dermatology” Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
March 2026 in “Mendeley Data” Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.
April 2023 in “Journal of Investigative Dermatology” Blocking casein kinase 1 in skin cells can help melanocyte precursors move better, potentially helping with conditions like vitiligo or gray hair.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
May 2026 in “Journal of Dermatological Treatment” Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
19 citations
,
March 2022 in “Journal of Infection” Canakinumab's effect on COVID-19 outcomes is unclear.
February 2026 in “Journal of Drugs in Dermatology” Janus kinase inhibitors are effective and safe for treating alopecia areata.
October 2021 in “Journal of Investigative Dermatology” Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
August 2025 in “Acta Dermato Venereologica” July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
11 citations
,
September 2024 in “American Journal of Clinical Dermatology” Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
3 citations
,
April 2024 in “International Journal of Women’s Dermatology” Access to JAK inhibitor therapy for alopecia areata patients is difficult, especially for racial minorities.
23 citations
,
November 2015 in “Phytotherapy Research” Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.
May 2018 in “The Journal of Immunology” A(1-7) treatment reduces symptoms of lupus in mice.